Oral Presentation of 6-Month BMD data at ASBMR

October 2021 - Entera presented the 6-month bone mineral density (BMD) data from its completed Phase 2 clinical trial of EB613, an oral formulation of human parathyroid hormone (1-34), or PTH, for the treatment of osteoporosis. The Late Breaking Presentation “A Six-month Phase 2 Study of Oral PTH in Postmenopausal Women with Low Bone Mass – 6 Month Bone Mineral Density (BMD) Results” was selected for a prestigious oral presentation, given by Entera’s Chief Medical Officer, Dr. Arthur Santora. Please see an article on the coverage of the oral presentation at the ASBMR.

 

pdfDownload presentation

pdfDownload MedpageToday article